Clinical Trials Logo

Healthy clinical trials

View clinical trials related to Healthy.

Filter by:

NCT ID: NCT05449249 Completed - Healthy Clinical Trials

Oral and Gut Microbiota Changes During Long-term Fasting in Humans

OralFast
Start date: September 1, 2022
Phase: N/A
Study type: Interventional

The aim of this longitudinal trial is to investigate the effects of a 10±3-day fasting period in 30 subjects. Changes in the oral and gut microbiota, halitosis, as well as inflammatory and antioxidative parameters and biomarkers of sulfur metabolism will be analysed.

NCT ID: NCT05448274 Completed - Healthy Clinical Trials

The Effects of a Ruminococcus Torques Strain Bacterium in Healthy Adults.

Start date: May 3, 2023
Phase: N/A
Study type: Interventional

A randomized, placebo controlled crossover study investigating the potential metabolic effects of the naturally occurring gut microbe Ruminococcus torques in healthy, overweight adults.

NCT ID: NCT05446610 Completed - Healthy Clinical Trials

Investigating Effects in Intestinal Permeability of Rich in Beta-glucans Pleurotus Eryngii Mushrooms Fermentation Supernatants: an Ex-vivo Study

FUNglucan
Start date: March 17, 2020
Phase: N/A
Study type: Interventional

The aim of the present study was to investigate the ability of Pleurotus eryngii mushrooms fermentation products (FS) to counteract induced intestinal hyperpermeability in human colonic tissues in an ex vivo system.

NCT ID: NCT05446350 Recruiting - Healthy Clinical Trials

Modulating Speech Perception With Current Stimulation

SPEECHSTIM
Start date: July 1, 2022
Phase: N/A
Study type: Interventional

This study aims to further develop tACS as a tool to improve speech perception, by manipulation of brain-speech synchronisation ("entrainment"), thereby transforming a promising approach into a technique that can benefit to society on a large scale.

NCT ID: NCT05446142 Completed - Healthy Clinical Trials

A Relative Bioavailability Study Evaluating Two New Encorafenib Formulations

ERBA
Start date: July 1, 2022
Phase: Phase 1
Study type: Interventional

Relative bioavailability study to evaluate the pharmacokinetics of two new encorafenib formulations

NCT ID: NCT05446103 Not yet recruiting - Healthy Clinical Trials

The Hypoalgesic Effects of Low Load Blood Flow Restriction Training (BFRT)

BFRT
Start date: July 2022
Phase: N/A
Study type: Interventional

A randomized controlled trial comparing the immediate effects of upper limb low-load blood flow restriction training (BFRT) with high load sham-BFRT on hypoalgesia and perceptual response in healthy adults

NCT ID: NCT05445622 Completed - Healthy Clinical Trials

Assessing Student Learning of Spinal Mobilization With Real-time Objective Feedback

Start date: April 10, 2019
Phase: N/A
Study type: Interventional

This is a research project on physical therapy education. Subjects will be recruited using convenience sampling from second-year physical therapy students on the campus of Youngstown State University. There are currently 28 students in the class. All students will be recruited to participate in the study. The objective of the study is to assess student learning of grades of spinal mobilization with real-time objective feedback.

NCT ID: NCT05444738 Recruiting - Healthy Clinical Trials

Effects of Oxytocin Administered Orally Using a Medicated Lollipop on Peripheral Concentrations and Attention

Start date: April 1, 2022
Phase: N/A
Study type: Interventional

The study will investigate whether oxytocin (24IU) administered orally using medicated lollipops results in increased peripheral oxytocin concentrations and can modulate social attention in an anti-saccade paradigm in the same way as when it is administered by intranasal or lingual routes.

NCT ID: NCT05444569 Completed - Healthy Clinical Trials

A Study of LY3537021 in Healthy Participants

Start date: August 8, 2022
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to evaluate the safety and tolerability of LY3537021 when administered in combination with glucagon-like peptide (GLP-1) receptor agonist called liraglutide in treatment-naïve healthy participants. The study will include 2 parts. The study will last up to 16 and 22 weeks for part A and B, respectively which includes a screening period of 6 weeks.

NCT ID: NCT05444556 Completed - Healthy Clinical Trials

A Study of Imlunestrant (LY3484356) in Female Healthy Participants

Start date: July 7, 2022
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to evaluate the effect of imlunestrant on repaglinide, omeprazole and dextromethorphan, and rosuvastatin and digoxin. The study will also investigate the effect of quinidine on imlunestrant in female healthy participants of non-childbearing potential. The safety and tolerability of imlunestrant will be investigated in female healthy participants of non-childbearing potential. The study will last approximately up to 32 days for each participant excluding the screening period.